Vima Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company, raised $60M in Series A funding.
The round was led by Atlas Venture, with participation from Access Industries and Canaan.
The company intends to use the funds to expand operations and its R&D efforts.
Led by CEO and Founder Bernard Ravina, Vima Therapeutics is a clinical-stage biotechnology company providing treatments of dystonia and related movement disorders by advancing an oral therapy designed to help patients with dystonia improve control of their movement by targeting the root cause of the disease.
It is advancing VIM0423 a potential first-in-class oral therapy, in a Phase 1 clinical trial, with plans to initiate Phase 2 by the fourth quarter of 2025.
Vima’s executive officers include:
- Judith Dunn, PhD, president and head of R&D, has 30+ years of drug development experience and has held leadership roles in biotech and pharma, including global head of clinical development at Roche.
- Jessica Fees, chief financial officer, brings over 20 years of finance and strategic leadership experience in the biotech industry. Prior to Vima, she served as chief financial officer at Surface Oncology.
- Ariel D. Jasie, JD, chief business officer and general counsel, has over 20 years of industry experience and has served as chief business officer and general counsel to multiple private biotech companies.
- Tushar Misra, PhD, chief technical officer, has been in the pharmaceutical industry for over 30 years and has worked across the entire value chain from R&D to Commercialization, with leadership roles at many companies, including Wyeth, Sepracor, and Takeda.
FinSMEs
30/05/2025